Company Description

Oruka Therapeutics, Inc., a biotechnology company, develops novel biologics for the treatment of chronic skin diseases.

Its lead products include ORKA-001 that targets p19 subunit of interleukin-23 (IL-23p19); and ORKA-002 that targets interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of psoriasis psoriatic arthritis, and other inflammatory diseases.

The company is based in Waltham, Massachusetts.

Oruka Therapeutics, Inc.

Country	United States
Founded	2004
CEO	Lawrence Klein

Contact Details

Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States
Website	orukatx.com

Stock Details

Ticker Symbol	ORKA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0000907654
ISIN Number	US6876041087
Employer ID	36-3855489
SIC Code	2835

Key Executives

Name	Position
Lawrence Klein	Chief Executive Officer
Arjun Agarwal	Chief Financial Officer
Laura Sandler	Chief Operating Officer
Alan Lada	Head of Investor Relations

Latest SEC Filings

Date	Type	Title
Dec 19, 2024	8-K	Current Report
Nov 26, 2024	EFFECT	Notice of Effectiveness
Nov 21, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Nov 18, 2024	8-K	Current Report
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	S-8	Securities to be offered to employees in employee benefit plans
Nov 14, 2024	8-K	Current Report
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings